Loading stock data…
Acumen Pharmaceuticals (ABOS)
$2.36+0.15 (+6.79%)
Market ClosedLast close Jun 26
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Acumen Pharmaceuticals, Inc. in the Healthcare sector is trading at $2.36 with a market capitalization of $170M. Wall Street consensus targets $7.40 (5 analysts), implying a +213.6% move over the next 12 months. The stock is currently 34% below its 52-week high of $3.60, remaining 4.9% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +213.6% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$21.15M↑ | -$25.20M↑ | -$26.51M↑ | -$41.75M↓ | -$30.37M |
| Net Income | -$20.74M↑ | -$25.14M↑ | -$26.45M↑ | -$40.95M↓ | -$28.80M |
Peer Comparison
JNJUNHPFE
Fundamentals
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phas...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$170.10M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-129.49%
Volume
Today's trading volume
5.57M
Recent News
Acumen Nominates 2 Therapies to Treat Alzheimer’s Disease
By Karen Roman Acumen Pharmaceuticals, Inc. (Nasdaq: ABOS) said it nominated ACU301 and ACU401, two candidates in its Enhanced Brain Delivery program, to treat Alzheimer’s Disease. The nomination comes after the company exercised its option with JCR Pharmaceuticals as part of a previously signed agreement, it stated. Register for our weekly newsletter HERE “We are […] The post Acumen Nominates 2 Therapies to Treat Alzheimer’s Disease appeared first on ExecEdge.
Acumen Pharmaceuticals Inc (ABOS) Q1 2026 Earnings Call Highlights: Strategic Advances Amid ...
Acumen Pharmaceuticals Inc (ABOS) showcases promising developments in Alzheimer's treatment and cost management, despite reporting a net loss for the quarter.
Acumen Pharmaceuticals Q1 Earnings Call Highlights
Acumen Pharmaceuticals (NASDAQ:ABOS) said its Phase 2 ALTITUDE-AD trial of sabirnetug remains on track, with top-line results expected late in 2026, as the company continues to advance its broader Alzheimer’s disease pipeline. On the company’s first-quarter 2026 earnings call, Chief Executive Offic
Acumen Pharmaceuticals (ABOS) Loses 33.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
The heavy selling pressure might have exhausted for Acumen Pharmaceuticals (ABOS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Is Acumen Pharmaceuticals (ABOS) Stock Outpacing Its Medical Peers This Year?
Here is how Acumen Pharmaceuticals, Inc. (ABOS) and ADC Therapeutics SA (ADCT) have performed compared to their sector so far this year.